

Cathy Cutler
Brookhaven National Laboratory, USA

Cathy S. Cutler, is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National Laboratory. Dr. Cutler is also chair of the committee on radiopharmaceuticals of the SNMMI and she sits on the executive board of directors of the Society of Radiopharmaceutical Sciences. She is also a board member of the Therapy Center of Excellence of the SNMMI as well as a board member of CMIIT of the SNMMI. She designed studies to determine how in vivo metabolism affects compounds distribution, clearance and target selectivity; and collaborated to radiolabel and evaluate peptides containing unique amino acids with modified side chains to bind metals such as technetium, rhenium and rhodium. Dr. Cutler worked at the University of Missouri Research Reactor Centers Radiopharmaceuticals Group till June of 2015. The MIRP group at Brookhaven produces both Sr-82 and Ge-68 for commercial production as well as a number of research radioisotopes and is currently evaluating the accelerator production of Ac-225. Her research focuses on developing high specific activity radioisotopes for Theranostic applications. Her primary interests are in imaging to inform radiotherapy. She brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.